Natural killer cells and tumor therapy

Area of Science:

• Immunology
• Oncology
• Cancer Metastasis

Background:

• Natural killer (NK) cells are implicated in controlling the spread of cancer metastasis.
• Therapeutic strategies involving NK cells include activating endogenous NK cells or adoptive transfer of ex vivo activated NK cells.

Purpose of the Study:

• To review existing evidence on the role of NK cells in cancer metastasis control.
• To evaluate the therapeutic potential and limitations of NK cell-based therapies and biological response modifiers (BRMs).

Main Methods:

• Review of preclinical and clinical evidence regarding NK cell therapies and BRMs.
• Analysis of clinical trial data from adoptive immunotherapy (AIT) with activated NK (A-NK) cells and BRM administration.
• Consideration of factors influencing therapeutic efficacy, such as tumor-induced immunosuppression and treatment setting.

Main Results:

• Early clinical trials of AIT with A-NK cells indicate feasibility and lack of toxicity but do not allow firm conclusions due to small sample sizes.
• Trials with BRMs have shown limited correlation between clinical response/survival and NK cell activity, potentially due to advanced disease and tumor-induced immunosuppression.
• BRM therapy may be more effective in the adjuvant setting and when combined with monitoring of effector cell functions.

Conclusions:

• NK cell-based therapies hold therapeutic potential for controlling cancer metastasis.
• Optimizing NK cell activation and delivery, especially in earlier disease stages and adjuvant settings, is crucial for enhancing efficacy.
• A deeper understanding of NK cell biology in cancer patients is essential for designing next-generation clinical trials.